SPY328.79+2.27 0.70%
DIA266.72+2.37 0.90%
IXIC10,902.80+157.52 1.47%

Pfizer shares are trading higher after the company and BioNTech commenced a Phase 2/3 safety and efficacy clinical study to evaluate a single nucleoside-modified messenger RNA candidate from their BNT162 mRNA-based vaccine program, against SARS-CoV-2.

Benzinga · -